Global Rheumatoid Arthritis Market: Trends and Opportunities ( )

Similar documents
REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013

Rituxan (Rheumatoid Arthritis)

Orencia (Rheumatoid Arthritis)

Actemra (Rheumatoid Arthritis)

REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013

Global Long Acting Injectable Anti-psychotic Market: Size, Trends & Forecasts ( ) April 2017

Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis

ACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

Global End Stage Renal Disease (ESRD) Market With Focus on Dialysis Market ( Edition) July 2017

View Report Details. Global Aortic Aneurysm Market: Trends and Opportunities ( )

National Institute for Health and Clinical Excellence SCOPE. Rheumatoid arthritis: the management and treatment of rheumatoid arthritis in adults

REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023

The US Onychomycosis Market (2017 Edition) July 2017

Global Deaf/Hearing Aid Market: Trends and Opportunities ( )

REFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Global Clear Aligner Market: Size, Trends & Forecasts ( ) August 2016

REFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

Global Legal Cannabis Market: Size, Trends & Forecasts ( ) September 2018

Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research

Clinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44

Regulatory Status FDA approved indication: Kineret is an interleukin-1 receptor antagonist indicated for: (1)

Global Myasthenia Gravis Market: Size, Trends & Forecasts ( ) August 2017

Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts ( ) September 2016

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage

COSENTYX (secukinumab)

The US Meal Kit Market: Size, Trends & Forecasts ( ) August 2017

Specialty drugs are a significant cost trend driver for

US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts ( ) September 2016

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Global Influenza Vaccine Market: Industry Analysis & Outlook

Global Spine Market with Focus on Spinal Fusion: Industry Analysis & Outlook ( )

Global Peripheral Artery Disease Market: Trends & Opportunities ( ) February 2016

For Rheumatoid Arthritis

Global Health Functional Food Market: Size, Trends & Forecasts ( ) December 2016

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

Global Remote Cardiac Monitoring Market: Size, Trends & Forecasts ( )

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Global Stevia Market: Size, Trends & Forecasts ( ) July 2017

Cimzia. Cimzia (certolizumab pegol) Description

Psoriatic Arthritis- Secondary Care

BSR Biologics Register Rheumatoid Arthritis Clinical Baseline Form

Psoriatic Arthritis- Second Line Treatments

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Cimzia. Cimzia (certolizumab pegol) Description

Insight RHEUMATOID ARTHRITIS. Drug Class. Background, new developments, key strategies INTRODUCTION JOINT DAMAGE. 75% of RA patients are women

Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities ( )

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

Global Continence Care Market with Focus on Intermittent Catheter Market ( ) December 2016

The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015

Corporate Medical Policy

Corporate Medical Policy

ustekinumab (Stelara )

Global Pulse Oximetry Market: Trends and Opportunities ( )

Investor Presentation Post-Interim Results Update. September 2011

REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019

A Patient s Guide to. Treatments for Psoriatic Arthritis

Although this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023

The Patent Trial and Appeal Board ( Board ) has heard numerous petitions for

Drug Therapy Guidelines

Rheumatoid arthritis

See Important Reminder at the end of this policy for important regulatory and legal information.

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Dry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017

Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour

Rheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011

Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024

Development of Novel Anti-Calcineurin Drugs for the

Simponi / Simponi ARIA (golimumab)

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

Global Dravet Syndrome Market: Industry Analysis & Outlook ( )

ACTEMRA (tocilizumab)

Global Deaf/Hearing Aid Market ( Edition) July 2017

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022

Cimzia. Cimzia (certolizumab pegol) Description

Global Stevia Extracts Market Analysis By Type (Dried, Leaves, Powder, Liquid), Application, Region, Country: Opportunities and Forecast ( )

Sickle-cell Anemia Therapeutics Market in the US

More Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA)

STELARA (ustekinumab)

REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022

Pharmacy Medical Necessity Guidelines: Actemra (tocilizumab)

ADDITIONAL DOSAGE STRENGTHS OF OTREXUP (METHOTREXATE) INJECTION APPROVED BY FDA

Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru

REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

Practical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014

The Medical Letter. on Drugs and Therapeutics

Transcription:

Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)

Global Rheumatoid Arthritis Market Report Scope of the report The report titled Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2013-18). Further, key drug manufacturers of the global rheumatoid arthritis market like Abbvie Inc. (Humira), Amgen Inc. (Enbrel), Johnson & Johnson (Remicade), Roche Holdings AG (Actemra) are profiled in the report. Company Coverage Abbvie Inc. Amgen Inc. Johnson & Johnson Roche Holdings AG

Global Rheumatoid Arthritis Market Report Executive Summary Rheumatoid arthritis (RA) is a chronic inflammatory disorder that principally attacks synovial joints. It is one of the most common autoimmune diseases affecting people of all ages and races. RA affects the lining of joints, causing a painful swelling that can eventually result in bone erosion and joint deformity. It also leads to stiffness, and redness in the joints. The main factor causing rheumatoid arthritis remains unknown. However, according to studies around the world some of the genetic and environmental factors are found to be more probable causers. Treatment of Rheumatoid Arthritis involves frequent drugs administration as RA is a progressive and incurable disease. Drugs used for treatment of RA are classified as first line agents- consisting of non steroidal anti-inflammatory drugs (NSAIDs) and steroids such as glucocorticoids and second line agents- consisting of disease modifying anti-rheumatic drugs such as chloroquine, gold salts, penicillamine, cyclosporine, and several biological agents like TNF-α and interleukin-1 inhibitors. Global rheumatoid arthritis market is driven by increase in incidences of RA patients, global ageing population and increasing healthcare expenditure by government of various nations. Factors which are affecting pharmaceutical companies are pricing pressure, patent expiries of RA drugs, high costs of treatments involved and escalating R&D costs. The market is characterized by use of auto-injectors by patients for RA treatment, increase in RA cases in women and FDA approvals for RA drugs.

Global Rheumatoid Arthritis Market: Overview Rheumatoid arthritis, or RA, is a form of chronic inflammatory disorder that typically affects the small joints of hands and feet. It is an autoimmune disease which occurs when a person s immune system mistakenly attacks body's tissues. Global Rheumatoid Arthritis Market Size, 2010-12 (US$ Billions) Global Rheumatoid Arthritis Market Size Forecast, 2013E-18E (US$ Billions) 2010 2011 2012E 2013E 2014E 2015E 2016E 2017E 2018E Market size of global rheumatoid arthritis market is expected to reach to US$ billions in the year 2018, from US$ billions in 2012 by growing at a CAGR of %. Growth in the market is due to.

s Market Market Size, 2010-12E (US$ Billions) Market Share by Types (2013E) Enbrel cc% Others dd% Humira aa% 2010 2011E 2012E Market Size Forecast, 2013E-18E (US$ Billions) B bb% Market Share Forecast (2016E) Enbrel mm% Others nn% Humira kk% 2013E 2014E 2015E 2016E 2017E 2018E B jj%

Market Trends Auto-Injectors for Rheumatoid Arthritis Treatment Increase in Rheumatoid Arthritis in Women....... FDA Approvals of Rheumatoid Arthritis Drugs.. Licensing Deals.. Rheumatoid Arthritis Drugs in R&D Pipeline...